Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | BTK | Q06187 | 2/20 | 0.33 |
| ▸ | KIT | P10721 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | MAPK14 | Q16539 | 6/20 | 0.32 |
| ▸ | MET | P08581 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.32 |
| ▸ | BLM | P54132 | 2/20 | 0.31 |
| ▸ | WEE1 | P30291 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12161336 | 0.93 | P2RY12 (0.46) | P2RY12MEN1KMT2ABTKNPC1 | |
| SCHEMBL14228581 | 0.89 | P2RY12 (0.42) | P2RY12MEN1KMT2ABTKKIT | |
| SCHEMBL13638370 | 0.88 | P2RY12 (0.38) | P2RY12BTKNPC1RAB9AMAPK14 | |
| SCHEMBL9923204 | 0.86 | P2RY12 (0.41) | P2RY12MEN1KMT2AKITNPC1 | |
| SCHEMBL12177099 | 0.86 | P2RY12 (0.34) | P2RY12MEN1KMT2ABTKCA12 | |
| SCHEMBL9923187 | 0.85 | P2RY12 (0.37) | P2RY12MEN1KMT2ABTKKIT | |
| SCHEMBL9922732 | 0.85 | P2RY12 (0.42) | P2RY12MEN1KMT2ABTK | |
| SCHEMBL12177093 | 0.85 | P2RY12 (0.37) | P2RY12MEN1KMT2ABTKKIT | |
| SCHEMBL12177089 | 0.84 | MEN1 (0.41) | P2RY12MEN1KMT2AKITMAPK14 | |
| SCHEMBL13638714 | 0.84 | P2RY12 (0.46) | P2RY12MEN1KMT2ABTKKIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120149688-A1 | PLATELET ADP RECEPTOR INHIBITORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2012-06-14 | — | — | US | disclosed |
| US-7622474-B2 | Asulfonyl(urea, thiourea, guanidine, cyanoguanidine) compounds; cardiovascular disorders; thrombosis | PORTOLA PHARMACEUTICALS, INC. (US) | 2009-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149688-A1 | PLATELET ADP RECEPTOR INHIBITORS | TBXA2R, GP6, P2RY6 | P2RY12 18/4885MEN1 4499/4885KMT2A 3023/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.